Philippe Moreau

机构：Centre National de la Recherche Scientifique, Inserm, Hotel Dieu Hospital, Centre Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Nantes Université · ORCID：0000-0003-1780-8746

发表论文 2102 篇 · 总被引 104702 次 · h-index 153

代表论文

• Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial (2025 · The Lancet Oncology · 被引 14)
• Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network (2025 · HemaSphere · 被引 10)
• Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone (2025 · Blood · 被引 5)
• European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma (2025 · HemaSphere · 被引 5)
• Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study (2025 · Journal of Clinical Oncology · 被引 4)
• Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 3)